Botox, Xeomin, Nabota, Innotox, Coretox — Korean dermatology offers more botulinum brands than anywhere else. Most are clinically equivalent for typical aesthetic uses. Here's the honest comparison from a clinic that uses them daily.
Mostly equivalent. Brand premium is real. Price gap matters.
Five major botulinum toxin brands available in Korea: Botox (Allergan), Xeomin (Merz), Nabota (Daewoong), Innotox (Medytox), Coretox (Medytox). All are KFDA-approved botulinum toxin type A with comparable mechanism. Clinical efficacy is functionally equivalent for typical aesthetic uses(forehead, glabella, crow's feet, masseter). The differences are practical: brand premium pricing, antibody profiles, and slight onset/duration variations. Botox is the global brand with strongest clinical data and FDA approval — premium pricing reflects that. Xeomin's pure formulation has lower theoretical antibody risk for long-term repeat patients. Korean brands (Nabota, Innotox, Coretox) deliver clinically equivalent results at 20–40% lower cost. Most foreign patients at JRYN choose Botox or Xeomin for brand certainty; cost-conscious patients pick Korean brands.
Allergan's original. Global brand, strongest clinical data, FDA + KFDA + PMDA approved. ~$15/unit at JRYN. Premium pricing reflects brand recognition and global trial investment. Most foreign patients' default choice for brand certainty.
Merz's pure-formulation product. Lacks the complexing proteins of Botox — theoretically lower antibody formation in long-term repeat patients. FDA + KFDA approved. ~$13/unit. Some patients with prior botox resistance respond to Xeomin.
Daewoong Pharmaceutical's Korean brand. Marketed as Jeuveau in US. KFDA + FDA approved. ~$10/unit. Comparable clinical efficacy to Botox in head-to-head trials. Strong adoption among Korean clinics. Cost-effective alternative.
Liquid formulation pre-mixed (vs Botox's powder requiring reconstitution). Medytox's brand. KFDA approved. ~$11/unit. Liquid format reduces dosing variability — slight technical advantage. Some clinicians prefer for precision applications.
Medytox's purified formulation similar to Xeomin philosophy. Lower antibody risk profile. KFDA approved. ~$10/unit. Korean alternative to Xeomin at lower cost. Suitable for long-term repeat patients seeking pure formulation.
DaxibotulinumtoxinA. Marketed as longer-lasting (5–6 months vs typical 3–4). Limited Korean availability. Not used at JRYN currently. Available at some Seoul premium clinics on request. Significantly higher pricing.
→ Botox. Global brand recognition, strongest clinical data, premium experience. Pay slightly more for confidence on first international botox visit.
→ Nabota or Innotox. Korean brands deliver clinical equivalence at 20–35% lower cost. Save the difference for combination treatments.
→ Xeomin or Coretox. Pure formulations reduce antibody formation risk over years of repeat treatments. Both are excellent choices.
→ Innotox (liquid). Pre-mixed liquid format reduces reconstitution variability. Slight advantage for fine motor area applications.
→ Korean brand (Nabota, Innotox, or Coretox). Doubling down on Korean technology adoption — the same brands many Korean celebrities use.
→ Switch to Xeomin or Coretox. If prior Botox treatment showed reduced efficacy over time, antibody resistance possible. Pure formulations may restore response.
Botox: 3–7 days. Xeomin: 4–7 days. Nabota: 3–5 days. Innotox: 3–5 days (liquid format may slightly accelerate). Coretox: 4–7 days. Differences are minor — none more than ~24 hours apart.
Botox: 3–4 months typical. Xeomin: 3–4 months. Nabota: 3–4 months. Innotox: 3–4 months. Coretox: 3–4 months. Functionally equivalent. Daxxify (not at JRYN) marketed at 5–6 months but real-world data variable.
Botox: highest theoretical (complex proteins). Xeomin: lowest (pure formulation). Coretox: low (similar to Xeomin). Nabota: moderate (similar to Botox). Innotox: moderate. For 10+ year repeat patients, pure formulations matter; for occasional users, all equivalent.
Botox: yes. Xeomin: yes. Nabota: yes (as Jeuveau in US). Innotox: not in US. Coretox: not in US. If you need FDA-approved specifically, Botox/Xeomin/Nabota only.
Botox, Xeomin, Nabota, Coretox come as powder requiring saline reconstitution at clinic. Innotox comes pre-mixed liquid. Reconstitution timing affects potency — JRYN reconstitutes within hours of use. Patients don't need to know the technical detail; just confirm fresh preparation.
All five brands require refrigeration. JRYN stores per manufacturer specs. Authentic vials have manufacturer holograms — verify on request. Counterfeit botulinum is a real problem at unscrupulous clinics; KHIDI-registered clinics like JRYN source through verified distributors.
No brand-specific aftercare differences. Universal rules: no lying down 4h, no exercise 24h, no alcohol 24h, no facials 48h, no sauna 48h. Mild redness/bruising at injection site possible regardless of brand. All flight-OK same day.
Switching between brands across years is fine — no clinical contraindication. JRYN tracks brand history per patient. Some patients find one brand subjectively works better; others see no difference. Document your response to optimize choice.
Dr. Lee Portrait
A medical decision should not feel rushed.
My job is to give you the 30 minutes you couldn't get at home
—
then deliver treatment that respects what made you fly here in the first place.
WhatsApp us your treatment areas, history, and budget. Within 24 hours we recommend specific brand with reasoning — Botox for global certainty, Xeomin for repeat patients, Korean brand for value. No upselling toward whichever costs more.
Individual results may vary. Content is for informational purposes only and is not a substitute for medical advice. Please consult a licensed medical professional before any procedure. Prices are estimates and may change. JRYN Dermatology is licensed under the Korean Medical Service Act.
